Biopharmaceutical manufacturer Genentech notified 340B entities this week that it is running out of Actemra IV (tocilizumab)—a key tool in treating hospitalized COVID-19 patients. It told entities they will be subject to the same allocation procedures as other buyers.
The U.S. Health Resources & Services Administration (HRSA) posted Genentech’s notice to entities on its website. As of Aug. 20, the notice said, 20, 10, and 4 milliliter vials were unavailable and 0.9 milliliter autoinjector pens were available on allocation. The U.S. Food and Drug Administration (FDA) drug shortages website this morning states that, as of Aug. 30, only 4 milliliter vials were unavailable.
Biopharmaceutical manufacturer Genentech notified 340B entities this week that it is running out of Actemra IV (tocilizumab)—a key tool in treating hospitalized COVID-19 patients.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
